Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Canadian biotechnology start AFYNIA LabsI picked up from McMaster University in Ontario, $ 5 million of seed financing to market blood test for endometrial-a medical condition that can affect people who have a uterus, causing problems such as chronic pelvic pain problems and fertility.
Endometriosis affects nearly 200 million people worldwide. It is still difficult to get a diagnosis, as some women have reported that it may take years – up to a decade of time – from doctors’ trips and invasive tests before obtaining confirmation. This, in turn, delays treatments that may reduce their pain or improve their chances of pregnancy. Diagnosis acceleration, so treatments can occur faster, is the AFYNIA task.
Participating founder Dr. Lauren Foster (in the image above the left) explains that endometriosis is not a single medical problem, but rather a syndrome or a series of different disorders that can appear with similar symptoms. Before starting the emerging, Foster was a professor of McMaster for more than two decades after an early profession as a research scientist.
The startup approach responds to the endometrium detection of this complexity by looking at a set of vital indicators. Specifically, its technique depends on the patient’s blood test due to the presence of microrna – small molecules playing a role in the operation of genes or stopping them.
Microrna Panel
AFYNIA, which is called Endomir, works by searching for a plate of these molecules using an algorithm to compare the level of expression from Microrna that revolves in the patient’s blood to people with surgically confirmed endometrium to reach the diagnosis.
“We have realized that we need to bypass just a single biological mark and look at a plate – a painting that has more consistency and reliability to capture the endometrium of different types and at different stages of the disease,” Foster told Techcrunch:
“The vital indicators that we see coverage different aspects of the disease. Therefore, they may participate in the growth of the new blood vessels, and they participate in inflammation, and participate in the new nerve growth factor, or the growth of the new peripheral nerves associated with pain – and so by targeting these different parts of the disease It is better to work together in a combination of anyone on its own.
“We use signs that reflect these different physiological functions of the disease, but we put them together in one plate, and we use our algorithm to determine whether or not it represents a danger to the disease,” Foster adds.
It argues that the test based on Microrna is a better way to do so than other methods-such as an attempt to discover endometrium by testing proteins-because the effects are more stable.
Microrna’s approach also allowed the start of operation to find “a group of signs that seem to be well working” to capture the endometrium, for each Foster, and to support the understanding of “what is confusing or overlapping factors.”
“Some of our competitors – they seem unable to do so,” she suggested.
Outside academic circles
While AFYNIA (Previously called AIMAFoster was founded in November 2021, and Foster says Endomir test technology depends on the long term of its research career that focused on ovarian organizing and uterine lining – which, since about 2015, which included looking at Microrna as well.
Foster previously participated in an attempt to innocence of a protein protein index to license a pharmaceutical company in Europe. But she says that the process of dealing with a commercial entity lacks the academic basis in science was frustrated. Consequently, besides a physician and co -founder now, Dr. Jocelin Wesel (also in the picture in the image of the feature above), they decided to take the IP address that they developed on the Microrna and the formation of their own company with the aim of marketing a non -surgical (meaning that there is no need for a surgical diagnosis). The uterus is for marketing.
Microrna’s use of the basis for testing the disease is not a new matter, and does not depend on Microrna’s diagnostic panels – and others try this type of approach to capture endometrium, also – but AFYNIA believes it has an advantage because it attacks the problem from the basis for academic discovery already. (Instead of the usual approach with many startups trying to develop a solution to break a commercial value problem I have identified.)
“We are really the first group, which found it as part of an academic laboratory, I realized its usefulness and decided to present it to the market,” says Dr. Jake Brigov, chief medical official at Startup.
“It was a profession to search, working on it and moving slowly towards Microrna,” Foster added, describing the “moment of Ah Ha”, which encouraged her to get out of the academic circles in the commercial field. She says the shark decreased after they managed to show that microrna blind tests on patients’ blood samples had a “very high level of agreement” with what surgeons were taking through gaseous tests.
“(These results have told us) We have something here interesting and deserves to be followed up,” she continues. “It is clear that there was a lot of work after that, to continue exploration, to improve, improve the reliability of the test, allergies.”
The start of the start refuses to detect any standards about the accuracy of the Endomir test for surgical diagnosis when we ask – saying that she wants to keep her data under the rear until she ends through the process of organizational approval in Canada to test a developed laboratory (LDT).
As part of this process, it will put its algorithm through clinical verification to show the clinical validity of the intended use cases-with a focus on the diagnosis of patients with chronic pelvic pain or infertility, which is both areas that treats are available to manage or improve diagnostic symptoms faster It has concrete benefits for patients.
Brigov says that the team is confident that they will be able to bring the test to the market in North America later this year – it hopes that the LDT will be approved during the next three months.
Canada will be the first test in the market in which it is published – perhaps as soon as this summer – with the launch of the United States scheduled early next year if everything is planning.
A better result of patients?
“The ordinary patient can wait from seven to eight years to diagnose (endometrium), some of which are more than a decade. Thus, although we cannot determine the amount of the reduction that we will be able to bring to these patients exactly, we are confident that we will be able To reduce this schedule significantly. “
The need for a patient to get his blood in the AFYNIA test to run is one of the maximum expansion. But he suggests that there is a positive aspect here in terms of the patient’s confidence – on the pretext that the diagnostic efforts that focus elsewhere (and do not require needles), for example the use of ultrasound and images analysis or even testing the effects of molecules in saliva, can suffer from lack of confidence between Patients and doctors responsible for requesting tests.
“We feel that we have a kind of best set of distinctive factors to be a leader in the market here,” he says. “The key there is the patient’s confidence and the balance between the level of invasion, if you will, and accurately. Patients trust the blood test. I think they are slightly skeptical of things like saliva tests, as you know, photography reports created from artificial intelligence. I think doctors are also.” .
Another “discriminatory factor” cost is the cost, which indicates: “We do this in a way that allows us to expand beyond where I think some of our competitors will have to land – based on the technology they have.” Reuse. “
Moreover, as the startup continues to develop its Microrna technology, Prigoff also says they hope that the test will work with only a drop of blood (i.e. from the tingling of the finger), instead of asking for a blood withdrawal. Although it confirms that this is not yet possible.
Although endometriosis is the place where AFYNIA puts all its energy at the present time, the startup wants to apply its approach to diagnosing health problems for other women – with a plan to provide a pipeline from Microrna tests to the market in the coming years. Although he is still tight on what might come, Prigoff says they want to provide patents before announcing additional tests.
The competitors are also chasing the promise of non -invasive tests for female health issues such as California Nextgen JinWhich explores the use of menstrual blood collected across the amounts to test endometriosis and other health conditions; and DotlabAnother American player, has developed a blood -based test for endometrial disease.
Similar health care platforms such as Alrara And research projects such as Citizen Indo It also seeks to meet the endometrial exhibitions with the support of managing their conditions or improving the understanding of the disease.
The AFYNIA Seed has led Bio-Rad Laborators, the LAB, with the participation of Fund America Fund, SOSV, The Capital Angel Network and Gaingels.
Before this funding, the Foster tour says that a startup raised about $ 1.5 million of financing before the seed, with support for its previous lifting from McMaster University and some seed investors, including SOSV and the Capital Angel network, as well as some of the New York Angel investors.